New 20-year data show a survival rate of 90% with few repeat surgeries after this complex operation that can only be ...

Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hrs [IST] ...

The researchers reviewed data on nearly 110,000 patients who underwent surgical replacement of aortic valves between the ages of 40 and 79. They found that in those aged 60 or younger, mechanical ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

Middle-aged adults who need an aortic valve replacement fare better with mechanical devices than with the valves made from ...

A study reveals that middle-aged adults fare better with mechanical aortic valves compared to animal tissue-based valves. The research, presented at the Society for Thoracic Surgery annual meeting, ...

Australia’s Therapeutic Goods Administration posted a draft guidance dealing with non-mandatory audits for premarket applications, which says that a transcatheter aortic valve replacement device that ...

These latest data reinforce years of smaller studies, but whether they should change practice is a matter of debate.

Navitor Vision enhances visibility and precision in TAVI procedures, offering a less invasive alternative to surgical aortic ...

Young patients who have undergone the Ross procedure for aortic valve disease have shown excellent long-term survival, the ...